Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease

Author(s):  
Dong Shin Kwak ◽  
Dae Won Jun ◽  
Jae Gu Seo ◽  
Won Seok Chung ◽  
Soon-Eung Park ◽  
...  
2017 ◽  
Vol 37 (04) ◽  
pp. 388-400 ◽  
Author(s):  
Ayesha Shah ◽  
Erin Shanahan ◽  
Graeme Macdonald ◽  
Linda Fletcher ◽  
Pegah Ghasemi ◽  
...  

AbstractThe authors conducted a meta-analysis of the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with chronic liver disease (CLD) and controls. Using the search terms “small intestinal bacterial overgrowth (SIBO)” and “chronic liver disease (CLD)” or “cirrhosis,” 19 case-control studies were identified. Utilizing breath tests, the prevalence of SIBO in CLD was 35.80% (95% CI, 32.60–39.10) compared with 8.0% (95% CI, 5.70–11.00) in controls. Using culture techniques, the prevalence was 68.31% (95% CI, 59.62–76.00) in CLD patients as compared with 7.94% (95% CI, 3.44–12.73) in controls. No difference between cirrhotic and noncirrhotic patients was found. SIBO is significantly more frequent in CLD patients as compared with controls. The association of SIBO and CLD was not confined to patients with advanced CLD, suggesting that SIBO is not a consequence of advanced liver disease but may play a role in the progression of CLD.


Sign in / Sign up

Export Citation Format

Share Document